Trump Executive Order Tracker | Akin Public Policy and Lobbying

Lowering Drug Prices by Once Again Putting Americans First (Trump EO Tracker)

April 15, 2025

Reading Time : 3 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order makes it the policy of the United States that Federal health care programs, intellectual property protections, and safety regulations are optimized to provide access to prescription drugs at a lower cost to American patients and taxpayers. 
 
The order directs: (a) the Secretary of Health and Human Services (“Secretary”) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program within 60 days of the order; (b) the Assistant to the President for Domestic Policy, in coordination with the Secretary, the Director of the Office of Management and Budget (OMB Director), and the Assistant to the President for Economic Policy to provide recommendations to the President on how best to stabilize and reduce Medicare Part D premiums within 180 days of the order; and (c) the Secretary to work with Congress to modify the Medicare Drug Price Negotiation Program.
 
The order also contains the following directions and deadlines:

  • Within one year of the order, the Secretary shall take steps to improve the ability of the Medicare program to obtain better value for high-cost prescription drugs and biological products covered by Medicare.
  • Within 180 days of the order, the Secretary shall publish a plan to conduct a survey to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments. Upon the survey’s conclusion, the Secretary shall propose adjustments that would align Medicare payment with the cost of acquisition.
  • Within 180 days of the order, the OMB Director, the Assistant to the President for Domestic Policy, and the Assistant to the President for Economic Policy shall work with the Secretary to recommend to the President how best to ensure that manufacturers pay accurate Medicaid drug rebates, promote innovation in Medicaid drug payment methodologies, link payments for drugs to the value obtained, and support States in managing drug spending.
  • Within 90 days of the order, the Secretary shall take action to ensure future grants under section 330(e) of the Public Health Service Act, as amended, 42 U.S.C. 254b(e), are conditioned upon health centers establishing practices to make insulin and injectable epinephrine available at or below the discounted price paid by the health center grantee or sub-grantee under the 340B Prescription Drug Program (plus a minimal administration fee) to individuals with low incomes.
  • Within 90 days of the order, the Assistant to the President for Domestic Policy, in coordination with the Secretary, the OMB Director, and the Assistant to the President for Economic Policy, shall provide recommendations to the President on how best to promote a more competitive and transparent pharmaceutical value chain that delivers lower drug prices for Americans.
  • Within 180 days of the order, the Secretary, through the Commissioner of Food and Drugs, shall issue a report providing administrative and legislative recommendations to: (a)  accelerate approval of generics, biosimilars, combination products, and second-in-class brand name medications; and (b)  improve the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
  • Within 90 days of the date of this order, the Secretary, through the Commissioner of Food and Drugs, shall take steps to streamline and improve the Importation Program under section 804 of the Federal Food, Drug, and Cosmetic Act to make it easier for States to obtain approval without sacrificing safety or quality.
    Within 180 days of the order, the Secretary shall evaluate and propose regulations to ensure that payment within the Medicare program is not encouraging a shift in drug administration volume away from less costly physician office settings to more expensive hospital outpatient departments.
  • Within 180 days of the order, the Secretary of Labor shall propose regulations pursuant to improve employer health plan fiduciary transparency into the direct and indirect compensation received by pharmacy benefit managers.
  • Within 180 days of the order, the Secretary or his designee shall conduct joint public listening sessions with the appropriate personnel from the Department of Justice, the Department of Commerce, and the Federal Trade Commission and issue a report with recommendations to reduce anti-competitive behavior from pharmaceutical manufacturers.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

July 24, 2025

Directs federal agencies to support the expanded use of civil commitment and institutional treatment for homeless individuals with serious mental illness or substance use disorders, while conditioning federal grants on the enforcement of anti-vagrancy laws and restricting funding for programs that permit drug use or prioritize housing without treatment. 
 
Federal agencies must promote the expanded use of civil commitment for homeless individuals with serious mental illness or substance use disorders, including by seeking the reversal of judicial precedents and termination of consent decrees that obstruct institutionalization. This order conditions federal grant funding on local enforcement of anti-vagrancy laws, such as bans on public drug use, camping, and squatting, and prohibits support for programs that emphasize housing without requiring treatment or accountability. The order also expands support for drug and mental health courts, permits more restrictive housing rules, and authorizes the collection and sharing of health data with law enforcement to enhance public safety. 

...

Read More

Trump Executive Order Tracker

July 17, 2025

This proclamation addresses the EPA’s April 5, 2024 final rule, National Emission Standards for Hazardous Air Pollutants:  Ethylene Oxide Emissions Standards for Sterilization Facilities Residual Risk and Technology Review, 89 Fed. Reg. 24090 (EtO Rule), which imposes new emissions-control requirements on commercial sterilization facilities. The proclamation declares that that certain stationary sources subject to the EtO Rule, as identified in Annex I of the proclamation, are exempt from compliance with the EtO Rule for a period of two years beyond the EtO Rule’s relevant compliance dates. During the two-year period, the exempted stationary sources will remain subject to the emissions and compliance obligations in effect prior to the issuance of the EtO Rule.

...

Read More

Trump Executive Order Tracker

July 17, 2025

Establishes Schedule G within the excepted service to cover noncareer, policymaking or policy-advocating positions that are normally subject to change with a presidential transition. The Director of the Office of Personnel Management (OPM) is directed to issue implementing regulations, and the Secretary of Veterans Affairs (VA) is tasked with appointing candidates aligned with the President’s policy priorities while remaining neutral on political affiliation. 

...

Read More

Trump Executive Order Tracker

July 17, 2025

Exempts six coal-fired power units in Ohio, Colorado, and Illinois from compliance with EPA’s revised Mercury and Air Toxics Standards (MATS) for two additional years, through July 8, 2029. Allows these facilities to operate under the previous MATS standards due to the unavailability of commercially viable compliance technology.

...

Read More

Trump Executive Order Tracker

July 17, 2025

Grants a two-year exemption from compliance with the EPA’s HON Rule for 25 specified chemical manufacturing facilities. Extends implementation of new hazardous air pollutant standards under Section 112 of the Clean Air Act, allowing affected facilities to continue operating under previous emissions rules.

...

Read More

Trump Executive Order Tracker

July 17, 2025

Grants a two-year exemption from the EPA’s Taconite Rule to seven iron ore processing facilities operated by U.S. Steel and Cleveland-Cliffs. Extends all compliance deadlines under the rule, maintaining pre-existing emissions standards to preserve domestic steel production capacity.

...

Read More

Trump Executive Order Tracker

July 7, 2025

Directs the Secretary of the Treasury to issue new guidance within 45 days to enforce the termination of Sections 45Y and 48E tax credits for wind and solar under the One Big Beautiful Bill Act, including restricting safe harbor use and preventing manipulation of “beginning of construction” rules. Treasury is also directed to implement the Act’s enhanced Foreign Entity of Concern (FEOC) restrictions within the same timeframe. Additionally, the Secretary of the Interior must review and revise any department policies that give preferential treatment to wind and solar over dispatchable energy sources.

...

Read More

Trump Executive Order Tracker

July 7, 2025

Through October 15, 2025, all executive departments and agencies are prohibited from filling vacant federal civilian positions or creating new ones unless exempted by law or approved under a limited review process administered by the Office of Personnel Management (OPM). Agencies must ensure any hiring aligns with the Merit Hiring Plan and are barred from using outside contracting to circumvent these restrictions.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.